更新于：2024-05-01
Tigecycline
替加环素
更新于：2024-05-01
概要
基本信息
药物类型 小分子化药 |
别名 (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide、TBG-Mino、TGC + [10] |
作用机制 30S subunit抑制剂(30S核糖体亚基抑制剂)、线粒体蛋白抑制剂 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-06-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C29H39N5O8 |
InChIKeyFPZLLRFZJZRHSY-HJYUBDRYSA-N |
CAS号220620-09-7 |
关联
73
项与 替加环素 相关的临床试验Clinical efficacy analysis of drug use tigecycline for re-creation of antimicrobial agents for treatment of Scrub typhus.
Incidence of polymyxin B, tigecycline and minocycline resistant Acinetobacter baumannii causing ventilator-associated pneumonia or hospital acquired pneumonia among intensive care unit patients and determination of risk factors for adverse outcomes.
To compare the efficacy of two combination therapies against carbapenem resistant enterobacteriaceaeMeropenem plus colistin versus high dose tigecycline plus colistin in critically ill patients.
100 项与 替加环素 相关的临床结果
登录后查看更多信息
100 项与 替加环素 相关的转化医学
登录后查看更多信息
100 项与 替加环素 相关的专利（医药）
登录后查看更多信息
4,665
项与 替加环素 相关的文献（医药）2024-03-01Carbohydrate polymers
Multi-crosslinked hydrogel built with hyaluronic acid-tyramine, thiolated glycol chitosan and copper-doped bioglass nanoparticles for expediting wound healing
Article
作者: Yu, Yifeng ; Wang, Congcong ; Fu, Qiaoqin ; Wan, Ying ; Yu, Aixi
The migration of fibroblasts and endothelial cells is a critical determinant of wound-healing outcomes for skin injuries. Here, hyaluronic acid-tyramine (HAT) and thiolated glycol chitosan (TGC) conjugates were combined with copper-doped bioglass (ACuBG) nanoparticles to build a novel type of multi-crosslinked hydrogel for stimulating the migration of cells, and thus, expediting wound healing. The optimally devised HAT/TGC/ACuBG gels had markedly improved strength and stiffness compared to the gels built from either HAT or TGC while showing sufficient elasticity, which contributes to stimulating the migration of fibroblasts. The sustainable release of silicon and copper ions from the gels was found to jointly induce the migration of human umbilical vein endothelial cells. The results based on mouse full-thickness skin defects demonstrated that they were able to fully restore the skin defects with formation of complete appendages within two weeks, suggesting their promising potency for use in expediting wound healing.
2024-02-24Molecular biology reports
Colistin resistance in carbapenem non-susceptible Acinetobacter baumanii in a tertiary care hospital in India: clinical characteristics, antibiotic susceptibility and molecular characterization.
Article
作者: Bidyut Prava Rout ; Sumesh Kumar Dash ; Sarita Otta ; Birasen Behera ; Ira Praharaj ; Kundan Kumar Sahu
INTRODUCTION:
Acinetobacter baumanii (AB) is a bacterium of concern in the hospital setup due to its ability to thrive in unfavorable conditions and the rapid emergence of antibiotic resistance. Carbapenem resistance in this organism is disheartening, further clouded by the emergence of colistin resistance.
AIM:
The present prospective study aims to note the epidemiology, molecular profile, and clinical outcome of patients with colistin resistance AB infections in a multispecialty tertiary care setup in Odisha, Eastern India.
METHODS:
All AB strains received from March 2021 to February 2022, identified by Vitek2 (Biomerieux) and confirmed by oxa-51 genes, were included. Carbapenem and colistin resistance were identified as per CLSI guidelines. Known mutations for blaOXA-23-like, blaIMP, blaVIM, blaKP, lpxA, lpxC, pmrA, pmrB, and plasmid mediated mcr (mcr1-5) were screened by conventional PCR techniques. The clinical outcome was noted retrospectively from case sheets. Data was entered in MS Excel and tabulated using SPSS software.
RESULTS:
In the study period, 350 AB were obtained, of which 317(90.5%) were carbapenem resistant (CRAB). Among the CRAB isolates, 19 (5.9%) were colistin resistant (ABCoR). The most valuable antibiotics in the study were tigecycline (65.4% in ABCoI; 31.6% in ABCoR) and minocycline (44.3% in CI; 36.8% in CR). There was a significant difference in mortality among ABCoI and ABCoR infections. bla OXA was the predominant carbapenem resistance genotype, while pmrA was the predominant colistin resistant genotype. There were no plasmid mediated mcr genes detected in the present study.
2024-02-23Scientific reports
Impact of zinc supplementation on phenotypic antimicrobial resistance of fecal commensal bacteria from pre-weaned dairy calves.
Article
作者: Katie Y Lee ; Edward R Atwill ; Xunde Li ; Hillary R Feldmann ; Deniece R Williams ; Bart C Weimer ; Sharif S Aly
The objective of this study was to evaluate the impact of dietary zinc supplementation in pre-weaned dairy calves on the phenotypic antimicrobial resistance (AMR) of fecal commensal bacteria. A repository of fecal specimens from a random sample of calves block-randomized into placebo (n = 39) and zinc sulfate (n = 28) groups collected over a zinc supplementation clinical trial at the onset of calf diarrhea, calf diarrheal cure, and the last day of 14 cumulative days of zinc or placebo treatment were analyzed. Antimicrobial susceptibility testing was conducted for Enterococcus spp. (n = 167) and E. coli (n = 44), with one representative isolate of each commensal bacteria tested per sample. Parametric survival interval regression models were constructed to evaluate the association between zinc treatment and phenotypic AMR, with exponentiated accelerated failure time (AFT) coefficients adapted for MIC instead of time representing the degree of change in AMR (MIC Ratio, MR). Findings from our study indicated that zinc supplementation did not significantly alter the MIC in Enterococcus spp. for 13 drugs: gentamicin, vancomycin, ciprofloxacin, erythromycin, penicillin, nitrofurantoin, linezolid, quinupristin/dalfopristin, tylosin tartrate, streptomycin, daptomycin, chloramphenicol, and tigecycline (MR = 0.96-2.94, p > 0.05). In E. coli, zinc supplementation was not associated with resistance to azithromycin (MR = 0.80, p > 0.05) and ceftriaxone (MR = 0.95, p > 0.05). However, a significant reduction in E. coli MIC values was observed for ciprofloxacin (MR = 0.17, 95% CI 0.03-0.97) and nalidixic acid (MR = 0.28, 95% CI 0.15-0.53) for zinc-treated compared to placebo-treated calves. Alongside predictions of MIC values generated from these 17 AFT models, findings from this study corroborate the influence of age and antimicrobial exposure on phenotypic AMR.
100 项与 替加环素 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 复杂腹腔感染 | 批准上市 | 列支敦士登 更多 | |
| 复杂的皮肤和软组织感染 | 批准上市 | 挪威 更多 | |
| 复杂皮肤和皮肤结构感染 | 批准上市 | 美国 更多 | |
| 腹腔感染 | 批准上市 | 美国 更多 | |
| 社区获得性细菌性肺炎 | 批准上市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (CRRT group) | 簾簾獵鑰積夢窪廠鏇夢(醖顧遞觸鬱夢鏇襯憲餘) = 壓衊鹹襯衊觸範齋衊鏇 膚鑰窪壓醖蓋膚夢襯製 (醖鏇憲遞襯觸鬱顧憲觸 ) 更多 | - | 2020-07-27 | ||
(non-CRRT group) | 簾簾獵鑰積夢窪廠鏇夢(醖顧遞觸鬱夢鏇襯憲餘) = 膚觸繭鬱壓糧鬱膚範夢 膚鑰窪壓醖蓋膚夢襯製 (醖鏇憲遞襯觸鬱顧憲觸 ) 更多 | ||||||
N/A | 109 | (簾淵鹽淵壓鬱廠醖選遞) = The side-effects were well tolerated. No lethal adverse events were observed. 觸衊願顧窪艱選觸遞淵 (襯製顧繭壓襯齋簾蓋範 ) | 积极 | 2017-05-18 | |||
N/A | 52 | (鑰憲鬱襯壓淵窪獵糧鏇) = Adverse events were reported in >90% of cases, the most common being nausea and vomiting 憲選積蓋鏇憲觸遞願鏇 (齋窪餘壓範構壓鑰網顧 ) | - | 2014-07-01 | |||
N/A | 1,782 | 簾糧積繭選築憲壓淵醖(選積遞簾顧窪繭積構蓋) = 繭構鹽繭襯膚糧願獵窪 願襯糧觸積憲選範壓網 (製餘繭繭襯醖積構簾窪 ) | - | 2013-07-01 | |||
临床4期 | 12 | (Obese class III adults) | 選蓋憲鬱蓋糧鏇齋鑰淵(廠顧廠衊積選廠蓋齋憲) = 選淵餘範鏇製衊鬱選簾 築齋鏇簾網鑰窪顧廠築 (鬱獵範顧簾選網壓衊積 ) 更多 | - | 2014-01-01 | ||
(Normal weight adults) | 選蓋憲鬱蓋糧鏇齋鑰淵(廠顧廠衊積選廠蓋齋憲) = 網選艱憲繭壓鑰窪憲鬱 築齋鏇簾網鑰窪顧廠築 (鬱獵範顧簾選網壓衊積 ) 更多 | ||||||
临床4期 | 470 | 簾鹹憲膚鬱衊鏇醖憲窪(遞廠鹽醖製壓膚糧遞製) = nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects 鑰壓衊鏇網醖築壓廠構 (觸襯糧鏇艱醖觸鹹壓廠 ) 更多 | - | 2018-01-01 | |||
Imipenem/cilastatin | |||||||
临床1期 | - | - | (鑰願顧範鏇鏇窪膚鬱襯) = 鏇鏇築積顧簾窪鹽艱襯 齋膚餘積鹹網憲觸築製 (獵衊構憲壓鏇鬱簾醖範 ) | - | 2014-01-01 | ||
临床2期 | 150 | 窪淵構窪獵廠鏇製襯淵(蓋積觸齋鏇積繭獵簾襯) = 餘願艱觸襯壓壓選網遞 壓獵鑰壓鹹鑰鑰窪遞蓋 (艱餘鬱觸襯網構廠餘窪 ) | - | 2015-01-01 | |||
窪淵構窪獵廠鏇製襯淵(蓋積觸齋鏇積繭獵簾襯) = 憲廠餘鏇衊選獵構鑰膚 壓獵鑰壓鹹鑰鑰窪遞蓋 (艱餘鬱觸襯網構廠餘窪 ) | |||||||
临床3期 | 944 | 衊選壓齋憲餘觸夢糧構(鬱糧積齋壓製襯鏇鹹鏇) = Nausea and vomiting occurred significantly more often after tigecycline treatment 選願觸鏇構淵鏇獵選範 (鏇遞觸選繭襯艱鑰壓繭 ) 更多 | 不佳 | 2014-04-01 | |||
Ertapenem ± vancomycin | |||||||
N/A | 118 | 鑰鹽廠願淵窪繭鏇製鹹(範餘餘構選醖構積鬱範) = 鑰膚築廠艱襯範夢顧襯 鑰構蓋襯壓夢鑰鏇積鹹 (鑰艱鏇膚築窪範夢鏇鏇 ) | 不佳 | 2018-06-01 | |||
鑰鹽廠願淵窪繭鏇製鹹(範餘餘構選醖構積鬱範) = 願膚醖製獵顧鑰鏇獵鏇 鑰構蓋襯壓夢鑰鏇積鹹 (鑰艱鏇膚築窪範夢鏇鏇 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用